Trump announces trade deal with EU following months of negotiations
CONCORD, Calif. - Cerus Corporation (NASDAQ:CERS), a biotech company with a market capitalization of $242 million and impressive revenue growth of 13% over the last twelve months, is set to present new clinical data on its INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion (ISBT) Congress, scheduled from May 31 to June 4, 2025, in Milan. The data will cover the system’s use for platelets, plasma, cryoprecipitated fibrinogen complex (IFC), and red blood cells. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, with analysts setting price targets significantly above current levels.
Chief Medical Officer Richard J. Benjamin highlighted the significance of the upcoming presentations, including positive results from the Phase 3 ReCePI study on red blood cells and the system’s efficacy in inactivating the California encephalitis virus. The company maintains a healthy financial position with a current ratio of 2.32, indicating strong ability to meet short-term obligations, while maintaining a gross profit margin of 56%.
Among the key presentations, the congress will feature a Cerus-sponsored symposium on June 1, focusing on the use of INTERCEPT platelet concentrates in France and their impact on adverse events, platelet use, and inventory management. The symposium will also discuss the safety and efficacy of INTERCEPT-treated platelets in neonates.
On June 2, oral presentations will delve into the distinct functional properties of pathogen-reduced platelet concentrates, the reduced need for hemoglobin in complex cardiac surgery using pathogen-reduced red cells, and a novel marker to track transfused pathogen-reduced red cells in sickle cell patients.
Selected poster presentations will cover a range of topics, including the stability of whole blood plasma after pathogen reduction treatment, the evaluation of cold-stored and room temperature double dose platelets treated with the INTERCEPT system, and the hemostatic functions of platelets under different storage conditions.
Cerus Corporation, headquartered in Concord, California, is committed to ensuring the safety of the global blood supply. The INTERCEPT Blood System for platelets and plasma is globally available and holds both CE mark and FDA approval. The system for Cryoprecipitation is approved in the U.S. for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex. The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S. With the next earnings announcement scheduled for July 31, 2025, investors can access comprehensive analysis and additional insights through InvestingPro, which offers exclusive access to detailed financial metrics, Fair Value calculations, and expert research reports covering over 1,400 US stocks.
The presentations at the ISBT Congress aim to reinforce the INTERCEPT Blood System’s role in enhancing blood safety and its broad applicability across various blood components. This information is based on a press release statement from Cerus Corporation.
In other recent news, Cerus Corporation reported its first-quarter 2025 earnings, noting a net loss of $7.7 million, or $0.04 per share, which met analyst expectations. Revenue for the quarter was $48.9 million, slightly below the forecast of $49.61 million, despite a 13% year-over-year increase in product revenue. North American revenues grew by 22%, while EMEA saw a slight decline. Cerus has also gained regulatory approval for its new blood safety device, INT200, from both the French and Swiss agencies, following a CE Mark authorization received earlier in the year. The INT200, an enhancement to the INTERCEPT Blood System, is designed to improve blood center operations with its LED-based illumination technology. Additionally, the company plans to transition from its older INT100 devices to the INT200 platform in the EMEA region over the next three years. Looking ahead, Cerus provided full-year 2025 product revenue guidance of $194-$200 million. The company is also preparing further regulatory submissions, including a PMA submission to the FDA planned for 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.